Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted VSports. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc. nih. gov. Updates regarding government operating status and resumption of normal operations can be found at OPM. gov.

Show Nav →
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

REV3L

Previous Assay Next Assay
Available Assays

Overview Data source: UniProt

Official Gene Symbol Other Aliases
REV3L POLZ, REV3
Sequence Length (AA) Molecular Weight (Da)
3130 352776
Protein Name
DNA polymerase zeta catalytic subunit
Sources
UniProt
PhosphoSitePlus ®
GeneCards 		Human Protein Atlas

Protein Sequence hover to view complete sequence

10 20 30 40 50
MFSVRIVTAD YYMASPLQGL DTCQSPLTQA PVKKVPVVRV FGATPAGQKT
60 70 80 90 100
CLHLHGIFPY LYVPYDGYGQ QPESYLSQMA FSIDRALNVA LGNPSSTAQH
110 120 130 140 150
VFKVSLVSGM PFYGYHEKER HFMKIYLYNP TMVKRICELL QSGAIMNKFY
160 170 180 190 200
QPHEAHIPYL LQLFIDYNLY GMNLINLAAV KFRKARRKSN TLHATGSCKN
210 220 230 240 250
HLSGNSLADT LFRWEQDEIP SSLILEGVEP QSTCELEVDA VAADILNRLD
260 270 280 290 300
IEAQIGGNPG LQAIWEDEKQ RRRNRNETSQ MSQPESQDHR FVPATESEKK
310 320 330 340 350
FQKRLQEILK QNDFSVTLSG SVDYSDGSQE FSAELTLHSE VLSPEMLQCT
360 370 380 390 400
PANMVEVHKD KESSKGHTRH KVEEALINEE AILNLMENSQ TFQPLTQRLS
410 420 430 440 450
ESPVFMDSSP DEALVHLLAG LESDGYRGER NRMPSPCRSF GNNKYPQNSD
460 470 480 490 500
DEENEPQIEK EEMELSLVMS QRWDSNIEEH CAKKRSLCRN THRSSTEDDD
510 520 530 540 550
SSSGEEMEWS DNSLLLASLS IPQLDGTADE NSDNPLNNEN SRTHSSVIAT
560 570 580 590 600
SKLSVKPSIF HKDAATLEPS SSAKITFQCK HTSALSSHVL NKEDLIEDLS
610 620 630 640 650
QTNKNTEKGL DNSVTSFTNE STYSMKYPGS LSSTVHSENS HKENSKKEIL
660 670 680 690 700
PVSSCESSIF DYEEDIPSVT RQVPSRKYTN IRKIEKDSPF IHMHRHPNEN
710 720 730 740 750
TLGKNSFNFS DLNHSKNKVS SEGNEKGNST ALSSLFPSSF TENCELLSCS
760 770 780 790 800
GENRTMVHSL NSTADESGLN KLKIRYEEFQ EHKTEKPSLS QQAAHYMFFP
810 820 830 840 850
SVVLSNCLTR PQKLSPVTYK LQPGNKPSRL KLNKRKLAGH QETSTKSSET
860 870 880 890 900
GSTKDNFIQN NPCNSNPEKD NALASDLTKT TRGAFENKTP TDGFIDCHFG
910 920 930 940 950
DGTLETEQSF GLYGNKYTLR AKRKVNYETE DSESSFVTHN SKISLPHPME
960 970 980 990 1000
IGESLDGTLK SRKRRKMSKK LPPVIIKYII INRFRGRKNM LVKLGKIDSK
1010 1020 1030 1040 1050
EKQVILTEEK MELYKKLAPL KDFWPKVPDS PATKYPIYPL TPKKSHRRKS
1060 1070 1080 1090 1100
KHKSAKKKTG KQQRTNNENI KRTLSFRKKR SHAILSPPSP SYNAETEDCD
1110 1120 1130 1140 1150
LNYSDVMSKL GFLSERSTSP INSSPPRCWS PTDPRAEEIM AAAEKEAMLF
1160 1170 1180 1190 1200
KGPNVYKKTV NSRIGKTSRA RAQIKKSKAK LANPSIVTKK RNKRNQTNKL
1210 1220 1230 1240 1250
VDDGKKKPRA KQKTNEKGTS RKHTTLKDEK IKSQSGAEVK FVLKHQNVSE
1260 1270 1280 1290 1300
FASSSGGSQL LFKQKDMPLM GSAVDHPLSA SLPTGINAQQ KLSGCFSSFL
1310 1320 1330 1340 1350
ESKKSVDLQT FPSSRDDLHP SVVCNSIGPG VSKINVQRPH NQSAMFTLKE
1360 1370 1380 1390 1400
STLIQKNIFD LSNHLSQVAQ NTQISSGMSS KIEDNANNIQ RNYLSSIGKL
1410 1420 1430 1440 1450
SEYRNSLESK LDQAYTPNFL HCKDSQQQIV CIAEQSKHSE TCSPGNTASE
1460 1470 1480 1490 1500
ESQMPNNCFV TSLRSPIKQI AWEQKQRGFI LDMSNFKPER VKPRSLSEAI
1510 1520 1530 1540 1550
SQTKALSQCK NRNVSTPSAF GEGQSGLAVL KELLQKRQQK AQNANTTQDP
1560 1570 1580 1590 1600
LSNKHQPNKN ISGSLEHNKA NKRTRSVTSP RKPRTPRSTK QKEKIPKLLK
1610 1620 1630 1640 1650
VDSLNLQNSS QLDNSVSDDS PIFFSDPGFE SCYSLEDSLS PEHNYNFDIN
1660 1670 1680 1690 1700
TIGQTGFCSF YSGSQFVPAD QNLPQKFLSD AVQDLFPGQA IEKNEFLSHD
1710 1720 1730 1740 1750
NQKCDEDKHH TTDSASWIRS GTLSPEIFEK STIDSNENRR HNQWKNSFHP
1760 1770 1780 1790 1800
LTTRSNSIMD SFCVQQAEDC LSEKSRLNRS SVSKEVFLSL PQPNNSDWIQ
1810 1820 1830 1840 1850
GHTRKEMGQS LDSANTSFTA ILSSPDGELV DVACEDLELY VSRNNDMLTP
1860 1870 1880 1890 1900
TPDSSPRSTS SPSQSKNGSF TPRTANILKP LMSPPSREEI MATLLDHDLS
1910 1920 1930 1940 1950
ETIYQEPFCS NPSDVPEKPR EIGGRLLMVE TRLANDLAEF EGDFSLEGLR
1960 1970 1980 1990 2000
LWKTAFSAMT QNPRPGSPLR SGQGVVNKGS SNSPKMVEDK KIVIMPCKCA
2010 2020 2030 2040 2050
PSRQLVQVWL QAKEEYERSK KLPKTKPTGV VKSAENFSSS VNPDDKPVVP
2060 2070 2080 2090 2100
PKMDVSPCIL PTTAHTKEDV DNSQIALQAP TTGCSQTASE SQMLPPVASA
2110 2120 2130 2140 2150
SDPEKDEDDD DNYYISYSSP DSPVIPPWQQ PISPDSKALN GDDRPSSPVE
2160 2170 2180 2190 2200
ELPSLAFENF LKPIKDGIQK SPCSEPQEPL VISPINTRAR TGKCESLCFH
2210 2220 2230 2240 2250
STPIIQRKLL ERLPEAPGLS PLSTEPKTQK LSNKKGSNTD TLRRVLLTQA
2260 2270 2280 2290 2300
KNQFAAVNTP QKETSQIDGP SLNNTYGFKV SIQNLQEAKA LHEIQNLTLI
2310 2320 2330 2340 2350
SVELHARTRR DLEPDPEFDP ICALFYCISS DTPLPDTEKT ELTGVIVIDK
2360 2370 2380 2390 2400
DKTVFSQDIR YQTPLLIRSG ITGLEVTYAA DEKALFHEIA NIIKRYDPDI
2410 2420 2430 2440 2450
LLGYEIQMHS WGYLLQRAAA LSIDLCRMIS RVPDDKIENR FAAERDEYGS
2460 2470 2480 2490 2500
YTMSEINIVG RITLNLWRIM RNEVALTNYT FENVSFHVLH QRFPLFTFRV
2510 2520 2530 2540 2550
LSDWFDNKTD LYRWKMVDHY VSRVRGNLQM LEQLDLIGKT SEMARLFGIQ
2560 2570 2580 2590 2600
FLHVLTRGSQ YRVESMMLRI AKPMNYIPVT PSVQQRSQMR APQCVPLIME
2610 2620 2630 2640 2650
PESRFYSNSV LVLDFQSLYP SIVIAYNYCF STCLGHVENL GKYDEFKFGC
2660 2670 2680 2690 2700
TSLRVPPDLL YQVRHDITVS PNGVAFVKPS VRKGVLPRML EEILKTRFMV
2710 2720 2730 2740 2750
KQSMKAYKQD RALSRMLDAR QLGLKLIANV TFGYTSANFS GRMPCIEVGD
2760 2770 2780 2790 2800
SIVHKARETL ERAIKLVNDT KKWGARVVYG DTDSMFVLLK GATKEQSFKI
2810 2820 2830 2840 2850
GQEIAEAVTA TNPKPVKLKF EKVYLPCVLQ TKKRYVGYMY ETLDQKDPVF
2860 2870 2880 2890 2900
DAKGIETVRR DSCPAVSKIL ERSLKLLFET RDISLIKQYV QRQCMKLLEG
2910 2920 2930 2940 2950
KASIQDFIFA KEYRGSFSYK PGACVPALEL TRKMLTYDRR SEPQVGERVP
2960 2970 2980 2990 3000
YVIIYGTPGV PLIQLVRRPV EVLQDPTLRL NATYYITKQI LPPLARIFSL
3010 3020 3030 3040 3050
IGIDVFSWYH ELPRIHKATS SSRSEPEGRK GTISQYFTTL HCPVCDDLTQ
3060 3070 3080 3090 3100
HGICSKCRSQ PQHVAVILNQ EIRELERQQE QLVKICKNCT GCFDRHIPCV
3110 3120 3130
SLNCPVLFKL SRVNRELSKA PYLRQLLDQF

Data source: UniProt

Protein Map Collapse protein map (V体育官网)

Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node
to view detailed assay information below
All other points link out to UniProt


Phosphorylation Acetylation Ubiquitylation Other

loading

Loader

Assay Details for CPTAC-944 Collapse assay details

Data source: Panorama

Official Gene Symbol
REV3L
Peptide Modified Sequence
SGTLS[+80.0]PEIFEK
Modification Type
Phospho (ST)
Protein - Site of Modification
1724
Peptide - Site of Modification
5
Peptide Start
1720
Peptide End
1730
CPTAC ID
CPTAC-944
Peptide Molecular Mass
1,286.5796
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM
Enrichment Method
IMAC
Matrix
cell lysate
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich

Publication

View Details (opens in a new window)

Kennedy JJ, Yan P, Zhao L, Ivey RG, Voytovich U, Moore HD, Lin C, Pogosova-Agadjanyan EL, Stirewalt DL, Reding KW, Whiteaker JR, Paulovich AG. Immobilized metal affinity chromatography coupled to multiple reaction monitoring enables reproducible quantification of phospho-signaling. Molecular and Cellular Proteomics. mcp V体育ios版. O115. 054940.

Assay Parameters Collapse assay parameters (V体育平台登录)

Data source: Panorama

Instrument
QTrap 5500 (Sciex)
Internal Standard
Peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
nanoLC-2D (Eksigent)
Column Packing
ChromXP C18-CL, 3 µm, 120 Å
Column Dimensions
75 µm x 15cm
Flow Rate
300 nL/min

Chromatograms

Data source: Panorama

view larger image
view larger image
view larger image

Response Curves

Data source: Panorama

view larger image
view larger image
view larger image

Retrieving Data

Loader

"VSports最新版本" Repeatability

Data source: Panorama

view larger image
  Average intra-assay CV
(within day CV)		 Average inter-assay CV
(between day CV)		 Total CV
equation		 n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
b8-98 (1+) 52.5 50.7 41.2 51.1 39.2 41.9 73.3 64.1 58.8 12 24 15
y6 (1+) 28.9 17 20.3 19 16.8 22.2 34.6 23.9 30.1 12 24 15
y7 (1+) 31.7 34.3 23 26 38.2 22.1 41 51.3 31.9 12 24 15
sum 29.7 16.6 15 19 15.8 13.8 35.3 22.9 20.4 12 24 15

Additional Resources and Comments (VSports)

Resources
Download SOPs
View Peptide in Panorama
View Protein in Panorama
Comments

"V体育2025版" Assay Details for CPTAC-3252 Collapse assay details

Data source: Panorama

Official Gene Symbol
REV3L
Peptide Sequence
SGTLSPEIFEK
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
N/A
Peptide Start
1720
Peptide End
1730
CPTAC ID
CPTAC-3252
Peptide Molecular Mass
1,206.6132
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM
Enrichment Method
IMAC
Matrix
cell lysate
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich

Publication

View Details (opens in a new window)

A Multiplexed Mass Spectrometry-Based Assay for Robust Quantification of Phosphosignaling in Response to DNA Damage. Whiteaker JR, Zhao L, Saul R, Kaczmarczyk JA, Schoenherr RM, Moore HD, Jones-Weinert C, Ivey RG, Lin C, Hiltke T, Reding KW, Whiteley G, Wang P, Paulovich AG. Radiat Res. 2018 Feb 23 V体育平台登录. doi: 10. 1667/RR14963. 1. [Epub ahead of print].

Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
6500 QTRAP (Sciex)
Internal Standard
synthetic peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
Ultra NanoLC 2D+ (Eksigent)
Column Packing
ReproSil-Pur C18-AQ 3um
Column Dimensions
100 x 0.075 mm
Flow Rate
300 uL/min

"VSports app下载" Chromatograms

Data source: Panorama

view larger image
view larger image
view larger image

Response Curves

Data source: Panorama

view larger image
view larger image
view larger image

Retrieving Data

Loader

Repeatability

Data source: Panorama

view larger image
  Average intra-assay CV
(within day CV)		 Average inter-assay CV
(between day CV)		 Total CV
equation		 n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y7 (1+) 16.4 11.7 9.4 17.9 19 12 24.3 22.3 15.2 15 15 15
y6 (1+) 19.3 10.7 9.4 32.4 17.2 9.4 37.7 20.3 13.3 15 15 15
y9 (1+) 41.6 28 15.8 49 27.2 14.6 64.3 39 21.5 15 15 15
sum 10.7 8.5 7.9 15.2 15.2 8.6 18.6 17.4 11.7 15 15 15

Additional Resources and Comments

Resources
Download SOPs
View Peptide in Panorama
View Protein in Panorama
Comments

Assay Details for CPTAC-3253 Collapse assay details

Data source: Panorama

Official Gene Symbol
REV3L
Peptide Modified Sequence
SGTLS[+80.0]PEIFEK
Modification Type
Phospho (ST)
Protein - Site of Modification
1724
Peptide - Site of Modification
5
Peptide Start
1720
Peptide End
1730
CPTAC ID
CPTAC-3253
Peptide Molecular Mass
1,286.5796
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM
Enrichment Method
IMAC
Matrix
cell lysate
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich

Publication

View Details (opens in a new window)

A Multiplexed Mass Spectrometry-Based Assay for Robust Quantification of Phosphosignaling in Response to DNA Damage. Whiteaker JR, Zhao L, Saul R, Kaczmarczyk JA, Schoenherr RM, Moore HD, Jones-Weinert C, Ivey RG, Lin C, Hiltke T, Reding KW, Whiteley G, Wang P, Paulovich AG. Radiat Res V体育官网入口. 2018 Feb 23. doi: 10. 1667/RR14963. 1. [Epub ahead of print].

Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
6500 QTRAP (Sciex)
Internal Standard
synthetic peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
Ultra NanoLC 2D+ (Eksigent)
Column Packing
ReproSil-Pur C18-AQ 3um
Column Dimensions
100 x 0.075 mm
Flow Rate
300 uL/min

Chromatograms

Data source: Panorama

view larger image
view larger image
view larger image

Response Curves

Data source: Panorama

view larger image
view larger image
view larger image

Retrieving Data

Loader

Repeatability (V体育官网入口)

Data source: Panorama

view larger image
  Average intra-assay CV
(within day CV)		 Average inter-assay CV
(between day CV)		 Total CV
equation		 n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y6 (1+) 26.4 10.4 8.8 32.4 14 11.8 41.8 17.4 14.7 15 15 15
y7 (1+) 13.8 15.1 7.7 32 16.5 14.5 34.8 22.4 16.4 15 15 15
y7-98 (1+) 21.7 11.4 15.3 23.6 14.6 15.4 32.1 18.5 21.7 15 15 15
y8-98 (1+) 23.5 9.5 9.5 29 9.7 12.8 37.3 13.6 15.9 15 15 15
y8 (1+) 33.6 13 8.5 40.4 15.6 20.7 52.5 20.3 22.4 15 15 15
sum 12.3 7.2 5.6 22 9.4 10.2 25.2 11.8 11.6 15 15 15

"VSports" Additional Resources and Comments

Resources
Download SOPs
View Peptide in Panorama
View Protein in Panorama
Comments